| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/27/2001 | US20010055607 Intranosally administering of anesthetics |
| 12/27/2001 | US20010055598 Mixture with solvent and hydrophobic carrier |
| 12/27/2001 | US20010055570 Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413957A1 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | CA2413878A1 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| 12/27/2001 | CA2413554A1 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes |
| 12/27/2001 | CA2413502A1 Tumour-cell specific gene expression and its use in cancer therapy |
| 12/27/2001 | CA2413452A1 Clk-2, cex-7 and coq-4 genes, and uses thereof |
| 12/27/2001 | CA2413435A1 A recombinant cell line expressing gpcrx11 as a functional receptor validated by angiopeptin and useful for screening of agonists and antagonists |
| 12/27/2001 | CA2413328A1 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 12/27/2001 | CA2413299A1 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus |
| 12/27/2001 | CA2413253A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | CA2412985A1 Hiv integrase inhibitors |
| 12/27/2001 | CA2412636A1 Method of treating cardiovascular disease using rapamycin |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2412362A1 Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
| 12/27/2001 | CA2412215A1 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | CA2412110A1 Osteolevin gene polymorphisms |
| 12/27/2001 | CA2412054A1 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 12/27/2001 | CA2411978A1 Transgenic mice containing targeted gene disruptions |
| 12/27/2001 | CA2411971A1 Proteases |
| 12/27/2001 | CA2411865A1 Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| 12/27/2001 | CA2411756A1 Mutation associated with epilepsy |
| 12/27/2001 | CA2411236A1 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii) |
| 12/27/2001 | CA2411100A1 New formulation comprising a betablocker and optionally a cholesterol-lowering agent |
| 12/27/2001 | CA2410864A1 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | CA2410632A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | CA2410371A1 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/27/2001 | CA2409776A1 G-protein coupled receptors |
| 12/27/2001 | CA2407896A1 Medium chain fatty acids applicable as antimicrobial agents |
| 12/26/2001 | CN1328569A TGF (b) 1 inhibitor peptides |
| 12/26/2001 | CN1328563A Organophosphorous compounds and use thereof |
| 12/26/2001 | CN1328467A Buffered composition for dialysis |
| 12/26/2001 | CN1328466A Use of antifungal agents for treating scleroses |
| 12/26/2001 | CN1328451A Drugs for improving vesical excretory strength |
| 12/26/2001 | CN1328447A Process for producing particles with converted amorphous and/or meta-stable crystalline region into crystalline state |
| 12/26/2001 | CN1328445A Pressurised metered dose inhalers |
| 12/26/2001 | CN1076624C Nasally administrable compositions |
| 12/26/2001 | CA2350043A1 Novel melanocortin -4 receptor sequences and screening assays to identify compounds useful in regulating animal appetite and metabolic rate |
| 12/25/2001 | US6333433 Coupling aliphatic aldehyde with alkylamine, reducing imine to secondary amine, reacting with protected hydroxyalkyl halide, deprotecting, quaternizing n-hydroxyalkyl group containing tertiary amine with alkyl halide or tosylate in polar solvent |
| 12/25/2001 | US6333356 Compounds for treating skin conditions |
| 12/25/2001 | US6333354 Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
| 12/25/2001 | US6333350 Use of nitric oxide donors and/or substrates or nitric oxide inhibitors for regulating cervical dilatation and extensibility |
| 12/25/2001 | US6333318 Used in therapy; for delivering recombinant proteins into a variety of cells within a patient |
| 12/25/2001 | US6333051 Nanogel networks and biological agent compositions thereof |
| 12/25/2001 | US6333046 For physiologically active peptide to be absorbed more efficiently via a mucosa, especially a large intestine mucosa |
| 12/25/2001 | US6333041 Nontoxic vernix compositions and method of producing |
| 12/25/2001 | US6333035 Administering monoclonal antibody against a human t-cell leukemia virus-derived transcription activating factor p40tax-induced cell membrane glycoprotein of 34 kda (gp34) in an amount effective for treating rheumatoid arthritis |
| 12/25/2001 | US6333034 Administering anti-properdin agent effective to selectively inhibit formation of an alternative complement pathway activation product |
| 12/25/2001 | US6333027 Non-stinging to the eyes |
| 12/25/2001 | CA2172779C Cgrp antagonist used for the treatment of pruritus and ocular or palpebral dysesthesia |
| 12/25/2001 | CA2066728C Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists |
| 12/20/2001 | WO2001096611A1 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| 12/20/2001 | WO2001096603A2 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | WO2001096598A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF |
| 12/20/2001 | WO2001096557A2 A human homologue of the dbf4/ask1 protein, nucleic acids, and methods related to the same |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096523A2 Polynucleotides related to colon cancer |
| 12/20/2001 | WO2001096450A2 Fast cure film forming formulation |
| 12/20/2001 | WO2001096390A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | WO2001096353A2 3'-PRODRUGS OF 2'-DEOXY-β-L-NUCLEOSIDES |
| 12/20/2001 | WO2001096347A1 HMG-CoA REDUCTASE INHIBITORS AND METHOD |
| 12/20/2001 | WO2001096346A1 Tricyclic compounds as mrp1-inhibitors |
| 12/20/2001 | WO2001096339A1 Novel telomerase inhibitors |
| 12/20/2001 | WO2001096312A1 Integrin ligands |
| 12/20/2001 | WO2001096300A1 Growth hormone secretagogues |
| 12/20/2001 | WO2001096283A2 Hiv integrase inhibitors |
| 12/20/2001 | WO2001095932A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR VIIa INHIBITOR |
| 12/20/2001 | WO2001095931A1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR |
| 12/20/2001 | WO2001095928A2 Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | WO2001095924A2 Method for treating a movement disorder |
| 12/20/2001 | WO2001095920A1 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 12/20/2001 | WO2001095919A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| 12/20/2001 | WO2001095906A1 Treatment and prevention of cardiac insulin resistance associated conditions |
| 12/20/2001 | WO2001095904A1 Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| 12/20/2001 | WO2001095903A1 5-ht3 receptor antagonists for treatment of disorders involving airway constriction |
| 12/20/2001 | WO2001095902A1 A composition comprising a combination of receptor agonists and antagonists |
| 12/20/2001 | WO2001095898A1 Analgesic and anti-inflammatory compositions containing cox-2 inhibitors |
| 12/20/2001 | WO2001095895A2 Methods of potentiating organic nitrates having vasodilating activity and formulations for the same |
| 12/20/2001 | WO2001095893A1 Use of an epoxy-steroidal aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095892A1 Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects |
| 12/20/2001 | WO2001095884A2 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | WO2001095872A1 Cosmetic and/or dermatological composition based on cocoa extracts |
| 12/20/2001 | WO2001095831A2 Cardiac disease treatment and device |
| 12/20/2001 | WO2001095711A2 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 12/20/2001 | WO2001088108A8 Neuronal serine-threonine protein kinase |
| 12/20/2001 | WO2001066102A3 Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| 12/20/2001 | WO2001064192A3 Use of benzothieno-2,3-d-pyrimidines with pde v inhibitory effect for the treatment of erectile dysfunction |
| 12/20/2001 | WO2001056554A3 Use of retinoid-type compounds as antibacterial agents |
| 12/20/2001 | WO2001055725A3 Diagnosis of tauopathies determining tau/phospho-tau ratio |
| 12/20/2001 | WO2001055108A3 Use of spl a2 inhibitors for the treatment of inflammation |
| 12/20/2001 | WO2001052874A3 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 12/20/2001 | WO2001047511A3 Treatment of drug-resistant human immunodeficiency virus infection |
| 12/20/2001 | WO2001044295A3 Agonists and antagonists of the receptor gpr19 and their use in appetite control |
| 12/20/2001 | WO2001035937A3 Lipid complex of alkycyclines |
| 12/20/2001 | WO2001031016A3 Processed human chemokines phc-1 and phc-2 |